Urogen Pharma (NASDAQ:URGN) General Counsel Sells $143,971.08 in Stock

Key Points

• Urogen Pharma's General Counsel, Jason Drew Smith, sold 7,522 shares of stock, totaling $143,971.08, reducing his ownership by 15.35% to approximately $794,156.88.
• The company's stock has a current price of $19.22 and has seen a significant trading volume with a 52-week range between $3.42 and $19.74.
• Several analysts have set target prices for Urogen Pharma, with estimates ranging from $16.00 to $50.00, predominantly maintaining a "buy" rating.

Urogen Pharma (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,522 shares of the firm's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the sale, the general counsel directly owned 41,492 shares in the company, valued at $794,156.88. This represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Urogen Pharma Stock Up 1.8%

URGN stock traded up $0.34 during mid-day trading on Friday, reaching $19.40. The company had a trading volume of 1,007,990 shares, compared to its average volume of 1,235,309. The stock has a market capitalization of $896.28 million, a P/E ratio of -6.10 and a beta of 1.12. Urogen Pharma has a one year low of $3.42 and a one year high of $19.74. The stock's 50-day simple moving average is $12.52 and its two-hundred day simple moving average is $11.03.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The company had revenue of $20.25 million during the quarter, compared to the consensus estimate of $22.71 million. On average, research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC raised its stake in shares of Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in Urogen Pharma in the 4th quarter worth about $59,000. Lazard Asset Management LLC purchased a new position in Urogen Pharma in the 4th quarter worth about $67,000. GAMMA Investing LLC grew its stake in Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Urogen Pharma during the 4th quarter valued at about $101,000. 91.29% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

URGN has been the topic of several recent analyst reports. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the company a "buy" rating in a research report on Friday, June 13th. Scotiabank reissued an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Guggenheim reissued a "buy" rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a research report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $32.86.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.